Zobrazeno 1 - 10
of 1 835
pro vyhledávání: ''
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Randell Seaton, Ann G. Schwartz, Felicity W. K. Harper, Jennifer L. Beebe-Dimmer, Matthew R Trendowski, Christine M. Lusk, Mark K. Greenwald, Michael S. Simon, Julie J. Ruterbusch
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8151-8161 (2021)
Cancer Medicine
Cancer Medicine
Background Epidemiological studies of chemotherapy‐induced peripheral neuropathy (CIPN) have predominantly focused on non‐Hispanic White patients, despite the observation that African Americans are more likely to experience CIPN. To address this
Autor:
Stéphane Champiat, Christophe Massard, Anne-Laure Voisin, Capucine Baldini, Benjamin Besse, Cedric Pobel, Vincent Thomas de Montpréville, Laurence Albiges, Christina Mateus, Jérôme Le Pavec, Samy Ammari, Aurélien Marabelle, Noémie Chanson, Patricia Pautier, Jean-Marie Michot, Patricia Romano-Martin, Charlotte Cabanié, François-Xavier Danlos, Caroline Even, Olivier Lambotte, Sophie Hans, Emilie Routier, A. Laparra, Celine Boutros, Corinne Balleyguier, Romain David Seban, Samuel Dolidon, Caroline Robert
Publikováno v:
European Journal of Cancer. 156:46-59
Sarcoid-like granulomatosis (SLG) reaction caused by immunotherapy remains poorly understood. This study aims to investigate the outcome of patients with cancer and SLG associated with immunotherapy.Between April 2016 and June 2020, 434 patients with
Autor:
Alberto Zaniboni, Chiara Cremolini, Gianluca Tomasello, Samanta Cupini, Laura Fanchini, Beatrice Borelli, Sara Lonardi, Gianluca Masi, Daniele Rossini, Angela Buonadonna, Carlotta Antoniotti, Veronica Conca, Gemma Zucchelli, Alfredo Falcone, Federica Marmorino, Margherita Ambrosini, Salvatore Caponnetto, Daniele Santini, Cosimo Rasola, Roberto Moretto
Publikováno v:
Br J Cancer
BACKGROUND: In mCRC, CEA is used to monitor response to systemic therapy together with imaging. After the end of induction, no major improvement in tumour shrinkage is expected, and the availability of a marker able to predict progressive disease (PD
Autor:
Raymond E. Baser, Tina Paul, Dristi Talukder, Mary Lou Galantino, Lillian M. Zhi, W. Iris Zhi, Qing S. Li, Clare Patterson, Christina Seluzicki, Lauren Piulson, Ting Bao
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 16, Pp 5456-5465 (2021)
Cancer Medicine, Vol 10, Iss 16, Pp 5456-5465 (2021)
Background Yoga is a meditative movement therapy focused on mind‐body awareness. The impact of yoga on health‐related quality of life (HRQOL) outcomes in patients with chemotherapy‐induced peripheral neuropathy (CIPN) is unclear. Methods We con
Autor:
Ian King, Joseph Alexander Ward, Beth Russell, Maria J. Monroy-Iglesias, Mieke Van Hemelrijck, Aadil A. Khan, Kelvin Ramsey
Publikováno v:
European Journal of Cancer. 151:233-244
Background Lymphoedema after cancer treatment is a chronic and disabling complication that presents a significant health care burden during survivorship with limited treatment options. Vascularised lymph node transfer (VLNT) can reconstruct lymphatic
Autor:
Sophie Alberdine Kurk, Bart A. W. Jacobs, Jacob Hendrik Beijnen, Neeltje Steeghs, Thomas P.C. Dorlo, Laura Molenaar-Kuijsten, Anne Maria May, Alwin Dagmar Redmar Huitema
Publikováno v:
Cancer medicine, 10(14), 4781-4789. John Wiley and Sons Ltd
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Background A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water
Autor:
Mikyung Kim, Ae Ran Kim, Joo-Hee Kim, Jung Hyo Cho, Kyungsun Han, Hyo-Ju Park, Yeon Cheol Park, Ojin Kwon, Yang Chun Park, Eun-Jung Kim, Junhwan Lee
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4721-4733 (2021)
Cancer Medicine
Cancer Medicine
Cancer‐related fatigue (CRF) is one of the most common chronic symptoms experienced by cancer patients. As moxibustion is a popular traditional therapy for managing fatigue, it can be an alternative strategy to treat CRF as well. Therefore, we rigo
Autor:
Stephane Ferretti, Sébastien Jeay, Ensar Halilovic, Claire Fabre, Laurence Van Bree, Christophe Meille, Jens Wuerthner, Florence Hourcade-Potelleret, Sebastian Bauer, Reinhard Dummer, Philippe A. Cassier, Astrid Jullion, George D. Demetri, Nelson Guerreiro, Daniel Shao-Weng Tan
Publikováno v:
British Journal of Cancer
Background CGM097 inhibits the p53-HDM2 interaction leading to downstream p53 activation. Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens. This first-in-human phase I study aimed at as
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow